Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6336950 | 0.98 | SMPD3 (0.46) | SMPD3GAACRHBPCRHR2CYP2C19 | |
| SCHEMBL23375711 | 0.86 | HRH3 (0.36) | SMPD3GAACRHBPCRHR2CYP2C19 | |
| SCHEMBL2412222 | 0.85 | CNR2 (0.43) | SMPD3CRHBPCRHR2CNR2NPC1 | |
| Hydrochloric Acid SCHEMBL6346443 | 0.84 | CNR2 (0.43) | SMPD3CRHBPCRHR2CNR2NPC1 | |
| SCHEMBL2415579 | 0.84 | CNR2 (0.46) | SMPD3CRHBPCRHR2CNR2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2420468 | 0.83 | CNR2 (0.45) | SMPD3CRHBPCRHR2CNR2ALDH1A1 | |
| SCHEMBL16931347 | 0.83 | HTR3A (0.57) | ALDH1A1KMT2AKDM4ECYP1A2MEN1 | |
| SCHEMBL21500076 | 0.81 | PDCD1LG2 (0.39) | SMPD3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL15300930 | 0.81 | OGA (0.54) | SMPD3GAACYP2C19CNR2PRKAB2 | |
| SCHEMBL21500090 | 0.81 | LRRK2 (0.38) | SMPD3PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1312606-B1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | OREAL (FR) | 2011-09-21 | — | — | EP | claimed |
| US-6837908-B2 | 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2005-01-04 | — | — | US | claimed |
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2003-09-04 | — | — | US | claimed |
| EP-1312606-A1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | L'OREAL (FR) | 2003-05-21 | — | — | EP | claimed |
| US-12466812-B2 | Pyridinyltriazine derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, ameliorating, or treating cancer comprising same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-11-11 | — | — | US | disclosed |
| WO-2024073745-A1 | INHIBITORS OF EGFR OR HER2 AND METHODS OF USE | ARBELLA THERAPEUTICS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20230027716-A1 | NOVEL PYRIDINYLTRIAZINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING CANCER COMPRISING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-01-26 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| EP-2892889-A1 | INHIBITOR COMPOUNDS | Cancer Research Technology Ltd (GB) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037750-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014037750-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-03-13 | — | — | WO | disclosed |
| EP-1312606-B1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | OREAL (FR) | 2011-09-21 | — | — | EP | disclosed |
| EP-1312606-B1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | OREAL (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-6837908-B2 | 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| EP-1312606-A1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | L'OREAL (FR) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | SMPD3 2943/4885GAA 2223/4885CRHBP 3472/4885 |
| US-11046688-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | SMPD3 2943/4885GAA 2223/4885CRHBP 3472/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | SMPD3 2943/4885GAA 2223/4885CRHBP 3472/4885 |
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | KRT18, DPYD, DSP | SMPD3 3953/4885GAA 3941/4885CRHBP 4650/4885 |
| US-12466812-B2 | Pyridinyltriazine derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, ameliorating, or treating cancer comprising same | FGFR3, FGFR1, FGFR4 | SMPD3 3513/4885GAA 4556/4885CRHBP 3604/4885 |
| US-20230027716-A1 | NOVEL PYRIDINYLTRIAZINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING CANCER COMPRISING SAME | FGFR3, FGFR1, FGFR4 | SMPD3 3772/4885GAA 4617/4885CRHBP 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.